Canada-based biopharmaceutical company Rakovina Therapeutics Inc (TSX-V: RKV) (FSE: 7JO0) announced on Thursday that its executive chairman, Jeffrey Bacha, and chief financial officer, Dr. David Kideckel, will attend and present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place 8-10 September in New York City.

The company says that Bacha will present an overview of Rakovina's research and development pipeline, corporate strategy, and upcoming milestones. The presentation will be accessible to registered conference attendees, with a recording made available on Rakovina's website and social media channels following the event. Throughout the conference, management will also participate in one-to-one meetings with institutional investors.

"We welcome the opportunity to meet with global investors at H.C. Wainwright to discuss how Rakovina is building value through our AI-enabled pipeline," said Bacha. "With the achievement of recent milestones in our programs and the advancement toward a JV partnership, we are well positioned for the next phase of development."

The H.C. Wainwright 27th Annual Global Investment Conference will take place at the Lotte New York Palace Hotel in New York City, with both in-person and virtual participation available. This gathering convenes public companies, industry executives, institutional investors, private equity firms, and venture capitalists to engage in a programme featuring keynote speakers, one-on-one investor meetings, and networking opportunities alongside presenting company sessions HCW Events.